

case reference: OZP.261.10.2026

registration no.: IF/ZNP-10/2026

Kraków, 01 April 2026

INVITATION TO SUBMIT TENDERS

for

a comprehensive service for conducting specialized *in vitro* studies in the field of molecular and cellular pharmacology, involving the evaluation of the biological activity of a chemical compound the BioMAP platform offered by Eurofins Discovery, for the needs of the Maj Institute of Pharmacology, Polish Academy of Sciences in Kraków

PROCEEDINGS

for the award of a contract

with a value not exceeding PLN 170,000.00 net

Common Procurement Vocabulary:

Code CPV: 73111000-3 Laboratory research services.

The provisions of the Act of 11 September 2019 – Public Procurement Law (Journal of Laws of 2024, item 1320, as amended) shall not apply to this procedure pursuant to Article 2(1)(1) of the Act.

Contracting Authority:

Maj Institute of Pharmacology Polish Academy of Sciences

12 Smętna Street

31-343 Kraków

The subject of the contract concerns the project entitled: “Implementation of the grant entitled *Optimization of bioavailability and verification of the therapeutic potential of Tryptamide in neurological diseases.*”

Call No. 2024/ABM/03/KPO for scientific institutions for the implementation of application-oriented research in the biomedical field, implemented by the Contracting Authority.

The Maj Institute of Pharmacology, Polish Academy of Sciences in Kraków, located at 12 Smętna Street, invites you to submit a tender for a comprehensive service for the performance of specialized *in vitro* studies in the field of molecular and cellular pharmacology, involving the evaluation of the biological activity of a chemical compound the BioMAP platform offered by Eurofins Discovery, for the needs of the Maj Institute of Pharmacology, Polish Academy of Sciences in Kraków.

The Contracting Authority informs that the Act of 13 April 2022 on special measures to counteract support for aggression against Ukraine and to protect national security (consolidated text: Journal of Laws of 2025, item 514), hereinafter referred to as the “Act”, shall apply in this procedure.

Pursuant to Article 1(3) of the Act, in order to counteract support for the aggression of the Russian Federation against Ukraine that began on 24 February 2022, sanctions are applied to persons and entities entered on the list referred to in Article 2 of the Act, including exclusion from public procurement procedures or competitions conducted under the Act of 11 September 2019 – Public Procurement Law (Journal of Laws of 2024, item 1320, as amended), hereinafter referred to as the “PPL Act”.

Pursuant to Article 7(1) of the Act, the following shall be excluded from a public procurement procedure or competition conducted under the PPL Act:

1. a contractor or competition participant listed in the registers specified in Regulation (EC) No 765/2006 and Regulation (EU) No 269/2014, or entered on the list on the basis of a decision on entry on the list determining the application of the measure referred to in Article 1(3) of the Act;
2. a contractor or competition participant whose beneficial owner, within the meaning of the Act of 1 March 2018 on counteracting money laundering and terrorist financing (Journal of Laws of 2022, items 593 and 655), is a person listed in the registers specified in Regulation (EC) No 765/2006 and Regulation (EU) No 269/2014, or entered on the list, or who has been such a beneficial owner since 24 February 2022, provided that such person has been entered on the list on the basis of a decision determining the application of the measure referred to in Article 1(3) of the Act;
3. a contractor or competition participant whose parent undertaking, within the meaning of Article 3(1)(37) of the Act of 29 September 1994 on Accounting (Journal of Laws of 2021, items 217, 2105 and 2106), is an entity listed in the registers specified in Regulation (EC) No 765/2006 and Regulation (EU) No 269/2014, or entered on the list, or has been such a parent undertaking since 24 February 2022, provided that it has been entered on the list on the basis of a decision determining the application of the measure referred to in Article 1(3) of the Act.

The above exclusion shall apply for the duration of the above-mentioned circumstances.

I. DESCRIPTION OF THE SUBJECT OF THE CONTRACT

The subject of the contract is a comprehensive service for the performance of specialized *in vitro* studies in the field of molecular and cellular pharmacology, involving the evaluation of the biological activity of a chemical compound the BioMAP platform offered by Eurofins Discovery, for the needs of the Maj Institute of Pharmacology, Polish Academy of Sciences in Kraków.

The Contracting Authority does not allow the submission of partial tenders. The only part (task) constitutes:

Task No. 1	<p>Subject: A comprehensive service for the performance of specialized <i>in vitro</i> studies in the field of molecular and cellular pharmacology, involving the evaluation of the biological activity of a chemical compound the BioMAP platform offered by Eurofins Discovery, for the needs of the Maj Institute of Pharmacology, Polish Academy of Sciences in Kraków.</p> <p>Common Procurement Vocabulary (CPV): 73111000-3 Laboratory research services.</p> <p>The Contracting Authority does not allow the submission of variant tenders.</p>
------------	---

A tender may be submitted for one part only. Parts may not be divided by Contractors.

1. Subject of the contract

The subject of the contract is the provision of a research service consisting of advanced biological profiling using the BioMAP® Diversity PLUS® platform offered by Eurofins Discovery, for the purpose of evaluating the biological activity, mechanism of action, and safety of the tested compounds.

2. General Characteristics of the Tests

The tests performed using the BioMAP® Diversity PLUS® platform constitute an advanced tool for the comprehensive evaluation of the biological activity of tested compounds under *in vitro* conditions closely reflecting human physiology. The system is based on the use of primary human cells, often in co-culture systems, enabling the reproduction of complex cell–cell interactions and regulatory mechanisms occurring in tissues. The studies are conducted in a panel of 12 specialized biological models that simulate various tissue types and disease states, particularly those related to inflammatory, immunological, and tissue remodeling processes. These models are appropriately stimulated to reproduce pathological conditions and activate specific biological pathways characteristic of particular diseases. A key element of the tests is the simultaneous analysis of a broad panel of protein biomarkers (148 parameters), reflecting essential biological processes such as inflammatory response, immune system activation, angiogenesis, cell proliferation, and extracellular matrix remodeling. The obtained data allow for the creation of a comprehensive phenotypic profile of the tested compound. A distinctive feature of BioMAP® assays is the ability to compare obtained results with an extensive database containing activity profiles of thousands of known reference compounds. This enables identification of potential mechanisms of action, assessment of similarity to existing drugs, and predictive analyses regarding efficacy and safety. These tests are primarily applied at the drug discovery and early preclinical stages, supporting the selection of the most promising candidates for further development and reducing the risk of failure in subsequent stages.

3. Detailed Description of the Tests Included in the Order

The contract includes the execution of studies using the BioMAP® Diversity PLUS® platform, involving a comprehensive analysis of the biological activity of tested compounds in standardized *in vitro* cellular models.

3.1. Sample Preparation and Exposure

- delivery of test compounds by the Contracting Authority in the required form and concentration,
- preparation of dilution series (optionally – testing at multiple concentrations within biologically relevant ranges),
- incubation of compounds with cellular systems according to the established experimental protocol.

3.2. Test Systems (BioMAP® Models)

The studies will be conducted using a panel of 12 biological systems based on primary human cells, including, but not limited to:

- vascular endothelial cells,
- immune system cells (PBMCs, T and B lymphocytes, monocytes, macrophages),
- fibroblasts,
- keratinocytes,
- epithelial cells (including bronchial epithelial cells).

These systems often function as co-cultures and are appropriately stimulated to reproduce pathological conditions such as:

- inflammatory states (various immune response profiles, e.g., Th1/Th2),
- immune system activation,
- fibrotic processes,
- endothelial dysfunction,
- skin and respiratory diseases.

3.3. Scope of Biomarker Measurements

The tests will include analysis of 148 protein biomarkers, including:

- cytokines and chemokines,
- adhesion molecules,
- markers of cell activation and proliferation,
- growth factors,
- markers of extracellular matrix remodeling.

Measurements are performed using immunoassays or equivalent high-throughput techniques.

3.4. Evaluation of Biological Response

For each tested compound, its effect will be determined in terms of:

- expression levels of individual biomarkers,
- direction and magnitude of biological response,
- selectivity of action across different tissue models,
- potential cytotoxicity (based on cell integrity and viability).

3.5. Data Analysis

- development of a multiparametric phenotypic profile (fingerprint) for each compound,
- statistical analysis of biomarker changes relative to controls,
- identification of biologically significant effects.

3.6. Comparative and Predictive Analysis

- comparison of obtained profiles with a database containing over 4,500 reference compounds,
- identification of similarities to known therapeutic classes,

- inference of mechanism of action (MoA),
- indication of potential therapeutic applications,
- benchmarking against existing drugs.

4. Results and Reporting

As part of the contract, the Contractor shall provide:

- a detailed report including:
 - results for all analyzed biomarkers,
 - activity profiles across individual BioMAP® systems,
 - interpretation of results and mechanism of action,
 - safety and potential toxicity assessment,
 - comparative analysis,

data in a format enabling further analysis by the Contracting Authority.

II. DOCUMENTS TO BE SUBMITTED WITH THE TENDER

- 1) Completed and signed Appendix 1 to the Invitation – Tender Form (this Appendix shall constitute an attachment to the contract),
- 2) Signed Appendix 1A to the Invitation – Description of the Subject of the Contract (this Appendix shall constitute an attachment to the contract),
- 3) A current extract from the relevant register or from the Central Register and Information on Economic Activity, if separate regulations require entry in such a register, issued no earlier than 6 months prior to the deadline for submission of tenders – or an equivalent document for entities having their registered office or place of residence outside the Republic of Poland.
The provisions of the Regulation of the Minister of Development, Labour and Technology of 23 December 2020 on subjective evidence and other documents or statements that may be requested by the contracting authority from the contractor (Journal of Laws of 2020, item 2415) shall apply to statements and documents submitted by the Contractor in the procedure (in the case of Contractors having their registered office or place of residence outside the Republic of Poland – § 4 of the above Regulation).

III. TIME LIMIT FOR PERFORMANCE OF THE CONTRACT

The subject of the contract shall be performed within a period of **6 weeks (42 calendar days)** calculated from the date of delivery of the samples to the Contractor.

IV. METHOD OF PREPARATION OF THE TENDER

The tender should be prepared in Polish or English, typed or written using a computer or indelible ink, in written form under pain of nullity, i.e. hand-signed by persons authorized to make declarations of intent on behalf of the Contractor, in accordance with the Contractor's rules of representation (legible signature or signature together with legibly written name and surname, e.g. a name stamp), or in electronic form. The Contracting Authority allows submission of the tender in the form of a scan.

If the tender is signed by attorneys-in-fact, the Contractor shall attach powers of attorney authorizing them to sign the tender. All powers of attorney attached to the tender must be submitted in original form or as a notarized copy.

If Contractors jointly apply for the award of the contract, a power of attorney for the appointed representative must be attached to the tender.

The tender price (calculated in accordance with the description in Section VIII of the Invitation) shall be stated by the Contractor in the submitted tender.

Any corrections should be made clearly and initialed by the persons signing the tender.

A Contractor may submit only one tender. The tender may not contain variant solutions, in particular more than one price.

The Contractor may prepare the tender using the template constituting Appendix 1 to the Invitation. The tender (together with the documents referred to in Section II) should be sent in original or electronic form to the following e-mail address: dzp@if-pan.krakow.pl. The subject line of the message (or the envelope) should include:

**MAJ INSTITUTE OF PHARMACOLOGY
POLISH ACADEMY OF SCIENCES
12 Smętna Street, 31-343 Kraków**

Case reference: **OZP.261.10.2026**, Registration No.: **IF/ZNP-10/2026**

TENDER

for

“A comprehensive service for conducting specialized *in vitro* studies in the field of molecular and cellular pharmacology, involving the evaluation of the biological activity of a chemical compound the BioMAP platform offered by Eurofins Discovery, for the needs of the Maj Institute of Pharmacology, Polish Academy of Sciences in Kraków”,

or via the **Competitiveness Database** platform:

<https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/>

NOTE – The Contracting Authority recommends submitting the tender signed with a qualified electronic signature, a trusted signature, or a handwritten signature to the above e-mail address or via the Competitiveness Database portal. Submission of a scanned document containing a handwritten signature is permitted.

V. CONTACT PERSON ON THE PART OF THE CONTRACTING AUTHORITY

The person authorized to communicate with Contractors is Assoc. Prof. Katarzyna Szczepańska, tel.: +48 12 662 33 19, e-mail: dzp@if-pan.krakow.pl, Monday to Friday, 10:00 a.m. – 2:00 p.m.

VI. PLACE AND DEADLINE FOR SUBMISSION OF TENDERS

The tender should be submitted electronically via the Competitiveness Database portal <https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/> or by e-mail to: dzp@if-pan.krakow.pl, or delivered to the Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków – Administration Department (ground floor),



by **09 April 2026, by 10:00 a.m.**, which means that by the expiry of the above deadline the tender must physically reach the Contracting Authority. Tenders submitted after the deadline shall not be considered. NOTE – The Contracting Authority recommends submitting the tender signed with a qualified electronic signature to the above e-mail address or via the Competitiveness Database portal. The Contracting Authority informs that the maximum size of attachments sent by e-mail is 10 MB. In case of problems with sending, please divide one message into several smaller ones not exceeding 10 MB. **Opening of tenders shall take place on 09 April 2026 at 11:00 a.m.** at the seat of the Contracting Authority – the Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków. Information from the opening of tenders shall be published without delay in the Competitiveness Database or sent to the Contractors who submitted tenders.

VII. CRITERIA AND METHOD OF EVALUATION OF TENDERS

The sole criterion for **evaluation of tenders** (with a weight of 100%) is **price**, i.e. the gross tender price.

The tender with the lowest gross price shall be selected as the most advantageous.

VIII. METHOD OF CALCULATING THE PRICE

By completing the Tender Form (Appendix 1), the Contractor shall indicate the net price, gross price and VAT for performance of the entire contract – in accordance with the Description of the Subject of the Contract set out in Section I above. The price should include all costs, discounts and rebates related to performance of the contract.

The tender price shall be stated in Polish zlotys (PLN) or in euros (EUR).

All prices and amounts in the tender should be stated with an accuracy of one grosz (in the case of prices in PLN) or one euro cent (in the case of prices in EUR), i.e. to two decimal places. In the case of a tender submitted in EUR, the Contracting Authority shall convert the price into PLN at the exchange rate of the National Bank of Poland on the date of publication of the Invitation to Submit Tenders.

If a tender is submitted whose selection would result in the Contracting Authority incurring a tax obligation in accordance with VAT regulations, the Contracting Authority shall, for the purpose of evaluating such a tender, add to the price presented therein the VAT amount that it would be obliged to settle in accordance with applicable regulations. The Contractor, when submitting the tender, shall inform the Contracting Authority that selection of the tender will result in a tax obligation, indicating the name (type) of goods whose supply would give rise to such obligation and their value excluding VAT.

The gross tender price is the price that shall be taken into account for evaluation of tenders (Section VII of the Invitation).

The gross tender price includes all costs related to performance of the service, i.e. transport costs, catering service, tableware and other costs resulting from performance of the subject of the contract, including the Contractor's risk arising from incorrect estimation of any costs related to

performance of the contract, as well as the impact of other factors that have or may have an influence on costs.

IX. PAYMENT TERMS

Remuneration shall be paid by bank transfer within 30 days from the date of submission of the invoice to the Contracting Authority, to the bank account indicated by the Contractor.

X. TENDER BINDING PERIOD

The Contractor shall be bound by the submitted tender for a period of 30 days. The tender binding period shall commence upon expiry of the deadline for submission of tenders specified in Section VI of the Invitation.

XI. MODEL CONTRACT

The model contract constitutes Appendix 2 to the Invitation.

Attachments:

- Tender Form (Appendix 1),
- Model Contract (Appendix 2).